Share on LinkedInShare on LinkedIn

ARTICLE · 29 AUGUST 2008

Schering Decided Against: Slated Deception Deficient

Pharmaceutical battles in the past and present, have hovered not merely the patent scenario, but have found a place in the various trademark clashes as well.

IndiaIntellectual Property

Pharmaceutical battles in the past and present, have hovered not merely the patent scenario, but have found a place in the various trademark clashes as well. The Indian Judiciary, over time has evolved its jurisprudence to tackle the issues of infringement amongst the similar commercial names adopted by rival companies. Vital considerations such as the nature of the drug (being a prescription drug or over-the-counter medication) and class of the drug (anti-cancer, ARV, etc.) form an inextricable part of the Court's deliberation while delivering its judgment. Several precedents have been laid in the regard, and the courts often revisit the dicta laid therein, to decide allegations of infringement and passing off. The Delhi High Court, rejected the grant of an interim injunction in Schering Corporation & Ors v. Getwell Life Sciences India Pvt. Ltd. [2008 (37) PTC 487 (Del.)] and Schering Corporation & Ors

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from